When will retatrutide be approved?

No approval date exists. The stated plan is an FDA filing in Q1 2027, after which review typically takes a year or more with no guaranteed outcome.

Have the Phase 3 trials finished?

The pivotal trials have reported. TRIUMPH-1 read out in May 2026 and TRIUMPH-2 and -3 in July 2026, with further readouts including maintenance-dosing studies still expected.

Can doctors prescribe it?

No. It has no marketing authorisation in any jurisdiction.

Does a positive Phase 3 mean approval is a formality?

No. Regulators assess the full dossier including manufacturing and long-term safety, and may request additional data.

Is Retatrutide FDA Approved? Regulatory Status

The short answer

No. Retatrutide is not approved by the FDA, EMA or MHRA and remains investigational everywhere. The position changed in substance during 2026: the pivotal TRIUMPH trials have now read out positively, and Eli Lilly has indicated it intends to file with the FDA in the first quarter of 2027. Filing begins a review; it is not an approval.

Key facts

FDA status: Not approved (investigational)
EMA status: Not approved
MHRA status: Not approved
Trial phase: Phase 3 complete on pivotal trials
TRIUMPH-1 readout: 21 May 2026: met primary endpoint
TRIUMPH-2 / -3 readout: July 2026: both met primary endpoints
Stated FDA filing: Q1 2027 (Biologics License Application)

What changed in 2026

Until May 2026 retatrutide was a compound with striking Phase 2 numbers and no pivotal data. That is no longer the case. TRIUMPH-1 reported topline results on 21 May 2026, and TRIUMPH-2 and TRIUMPH-3 followed in July, all meeting their primary endpoints. The regulatory status is unchanged (still not approved), but the reason has changed from "the evidence does not exist yet" to "the evidence exists and has not yet been submitted or reviewed".

Where does it stand in the approval process?

Lilly has stated an intention to submit a Biologics License Application to the FDA in the first quarter of 2027. Submission is the start of a formal review, which commonly runs a year or more, and regulators can request further data or decline. No MHRA or EMA filing timeline has been announced publicly, and a UK authorisation would be a separate decision from any FDA outcome.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £49.99

Does the orforglipron approval affect this?

No. The MHRA authorised orforglipron (Foundayo) on 10 August 2026, but marketing authorisations are granted to a specific product for a specific indication. One incretin being licensed carries no implication for the status of a different, investigational compound from the same company.

Is it legal to buy retatrutide?

In the UK retatrutide is supplied for laboratory research only. It is not a licensed medicine, cannot be prescribed or dispensed, and is not for human use outside a registered clinical trial. That position is unaffected by the trial results above.

Frequently asked questions

When will retatrutide be approved?: No approval date exists. The stated plan is an FDA filing in Q1 2027, after which review typically takes a year or more with no guaranteed outcome.
Have the Phase 3 trials finished?: The pivotal trials have reported. TRIUMPH-1 read out in May 2026 and TRIUMPH-2 and -3 in July 2026, with further readouts including maintenance-dosing studies still expected.
Can doctors prescribe it?: No. It has no marketing authorisation in any jurisdiction.
Does a positive Phase 3 mean approval is a formality?: No. Regulators assess the full dossier including manufacturing and long-term safety, and may request additional data.

Extended research context

The Retatrutide Research deep dive

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance. This is the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator (FDA, EMA, or MHRA) has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press, but the pharmacology is more nuanced than the label implies.

Research applications

▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
▸Reference material for teaching incretin pharmacology in university-level courses

Handling checklist

✓Store lyophilised vials at −20 °C; protect from light and humidity
✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
✓Once reconstituted, store at 2–8 °C and use within 28 days
✓Verify batch CoA: HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
✓Do not administer to humans or animals. Research use only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing retatrutide with tirzepatide in supplier catalogues

Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

✗ Using tap or filtered water for reconstitution

Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water, never lab DI water.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum

Is Retatrutide FDA Approved? Regulatory Status Explained